A review of public comments submitted to the Centers for Medicare and Medicaid Services in response to the 2022 National Coverage Decision on treatment for Alzheimer’s disease
Journal of Law and the Biosciences · 03.01.2025 · 12 (1)
DOI: 10.1093/jlb/lsaf004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Law and the Biosciences, online erschienen am 04.04.2025. Verfasst von Kaatje S Greenberg und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of Pennsylvania Carey Law School, 3501 Sansom Street, Philadelphia, PA 19104, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) is a neurodegenerative disease with devastating personal and social consequences. In June 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to aducanumab (Aduhelm; Biogen), a first-in-class monoclonal antibody (mAb) for treatment of AD. In July 2021, responding to the significant controversy sparked by aducanumab’s approval, the Centers for Medicare and Medicaid Services (CMS) opened a National Coverage Determination (NCD) analysis for mAbs intended for the treatment of AD. CMS received a record number of public comments on the proposed NCD, which included a proposal for coverage with evidence development (CED). We undertook an in-depth qualitative analysis of those comments. Broad themes included: the appropriateness of FDA’s approval of aducanumab; the nature of the relationship between CMS and FDA; anticipated downstream effects of CED on innovation and health equity; aducanumab’s cost, value, and affordability; and whether aducanumab offered patients hope. The aducanumab controversy occurred at the intersection of multiple contentious issues; in the discussion, we contextualize our findings within these broader debates. Though Biogen pulled aducanumab from the market in early 2024, the effects of the public discourse surrounding its approval and coverage have been long-lasting and far-reaching, affecting health law, policy, and clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Pennsylvania Carey Law School, 3501 Sansom Street, Philadelphia, PA 19104, USA.
- Department of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, 423 Guardian Drive, Philadelphia, PA 19104, USA.
- University of Pennsylvania School of Dental Medicine, 240 South 40th Street, Philadelphia, PA 19104, USA.
- University of Pennsylvania School of Nursing, 418 Curie Boulevard, Philadelphia, PA 19104, USA.
ORCID-Profile: Holly Fernandez Lynch, Emily A Largent
Zitieren
APA
Greenberg, K. S., Lynch, H. F., Nwakama, C., Frumovitz, J., Setru, S., Johnson, A. M., Shah, S. M., Schadt, L., McCoy, M. S., Hoffman, A. K., & Largent, E. A. (2025). A review of public comments submitted to the Centers for Medicare and Medicaid Services in response to the 2022 National Coverage Decision on treatment for Alzheimer’s disease. Journal of Law and the Biosciences, 12(1). https://doi.org/10.1093/jlb/lsaf004
Vancouver
Greenberg KS, Lynch HF, Nwakama C, Frumovitz J, Setru S, Johnson AM, et al. A review of public comments submitted to the Centers for Medicare and Medicaid Services in response to the 2022 National Coverage Decision on treatment for Alzheimer’s disease. Journal of Law and the Biosciences. 2025;12(1). doi:10.1093/jlb/lsaf004
BibTeX
@article{Greenberg2025,
author = {Greenberg, Kaatje S and Lynch, Holly Fernandez and Nwakama, Chisom and Frumovitz, Jonathan and Setru, Samarth and Johnson, Ariel M and Shah, Saloni M and Schadt, Liliana and McCoy, Matthew S and Hoffman, Allison K and Largent, Emily A},
title = {A review of public comments submitted to the Centers for Medicare and Medicaid Services in response to the 2022 National Coverage Decision on treatment for Alzheimer’s disease},
journal = {Journal of Law and the Biosciences},
year = {2025},
volume = {12},
number = {1},
doi = {10.1093/jlb/lsaf004}
}
EUVIMED